Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
Retrieved on:
Thursday, December 1, 2022
COVID-19, Medical school, ROAD, University, Cell, University of California, Davis, Pneumonia, Pain, Chronic lung disease, COPD, Degenerative disease, Acquisition, Patient, Pulmonology, Itch, Chronic obstructive pulmonary disease, FSE, Interstitial lung disease, Cell proliferation, JNX, Research, FDA, Inflammation, Drug development, UCD, COVID, Asthma, School, Therapy, UCAN, UC, Infarction, Stroke, Critical Care Medicine (journal), Acute respiratory distress syndrome, Office for National Statistics, Pharmaceutical industry, Medicine, Therma
Statins have been used clinically to treat high cholesterol levels which protect patients from heart attacks and strokes for over 35 years.
Key Points:
- Statins have been used clinically to treat high cholesterol levels which protect patients from heart attacks and strokes for over 35 years.
- When delivered via the inhaled route, the statins are targeted to the site of disease activity for greater therapeutic benefit.
- As well, we look forward to the promise that these statin treatments provide for chronic lung diseases including asthma and COPD."
- Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX).